Evidence map›Paper›PMID 38774494›Full record

ReviewCancer management and research2024

Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge.

Elizabeth Nally, Matthew Young, Vishwani Chauhan, Connor Wells, Bernadett Szabados, Thomas Powles, Francesca Jackson-Spence

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elizabeth NallyBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0009-0006-0665-5210
Matthew YoungBarts Cancer Institute, Queen Mary University of London, London, UK.
Vishwani ChauhanDepartment of Medical Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.ORCID 0000-0002-1865-3654
Connor WellsBarts Cancer Institute, Queen Mary University of London, London, UK.
Bernadett SzabadosBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-8786-0032
Thomas PowlesBarts Cancer Institute, Queen Mary University of London, London, UK.
Francesca Jackson-SpenceBarts Cancer Institute, Queen Mary University of London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upper tract urothelial carcinoma (UTUC) is an aggressive and difficult malignancy to treat. Owing to its rarity and the lack of specific high-level data, management mirrors that of urothelial cancer of the bladder (UCB). Over the past decade, UTUC has shown minimal improvement in survival rates. Its location makes the diagnosis and staging of UTUC more complex. Moreover, surgery often leads to a decline in renal function, rendering a proportion of patients ineligible for cisplatin. There is debate as to how best manage locally advanced UTUC perioperatively. Although immune checkpoint inhibitors (ICIs) have changed the treatment landscape for UCB, the response to ICIs in UTUC has been variable. With new technologies, our understanding of the molecular biology of UTUC has grown, helping to identify key molecular differences from UCB. This review summarises the evidence available on UTUC as a disease entity, discusses treatment in perioperative and metastatic settings, and considers future directions for the management of patients diagnosed with UTUC.

Indexed as

immunotherapytargeted therapyupper tracturothelial

Identifiers

PMID38774494
PMCPMC11107909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.